All In Biotech

BLA 761326 · Novo Nordisk INC

Awiqli Flextouch

Insulin Icodec · Solution

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Mar 26, 2026

Approved uses

2

Original approval plus efficacy supplements

Registered trials

36

15 Phase 3, 6 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 23, 2026 Supplement 1 · Efficacy · priority review LetterLabel
  • Mar 26, 2026 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • AWIQLI FLEXTOUCH · INSULIN ICODEC · INJECTION, SOLUTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Icodec" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 49 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.